Attorney Docket No.: Q92272

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/562,010

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [I]

$$X$$
 $COOR^1$
 H_2N
 $COOR^2$

[wherein R^1 and R^2 are the same or different, and each represents a hydrogen atom, a C_{1-10} alkyl group, a phenyl group, a naphthyl group, a C_{1-10} alkyl group substituted by one or two phenyl groups, a C_{2-10} alkenyl group, a C_{2-10} alkynyl group, a hydroxyl C_{2-10} alkyl group, a C_{1-10} alkyl group, a C_{1-10} alkyl group, an amino C_{2-10} alkyl group or a C_{1-10} alkyl group; X represents a hydrogen atom or a fluorine atom;

Y represents an amino group, $-SR^3$, $-S(O)_nR^7$, $-SCHR^3R^4$, $-S(O)_nCHR^3R^4$, $-NHCHR^3R^4$, $-NHCHR^3R$

Attorney Docket No.: Q92272

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/562,010

represents "a phenyl group substituted by one to five substituents selected from a group consisting of a halogen atom, a phenyl group, a C_{1-10} alkyl group, a C_{1-10} alkoxy group and a trifluoromethyl group";

 R^7 represents a C_{1-10} alkyl group, a phenyl group, a naphthyl group, a naphthyl group substituted by one to seven halogen atoms or a hetroaromatic group, or represents "a phenyl group substituted by one to five substituents selected from a group consisting of a halogen atom, a phenyl group, a C_{1-10} alkyl group, a C_{1-10} alkoxy group and a trifluoromethyl group"; and n represents integer 1 or 2)].

2. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [II]

[Wherein R^1 and R^2 are the same or different, and each represents a hydrogen atom, a C_{1-10} alkyl group, a phenyl group, a naphthyl group, a C_{1-10} alkyl group substituted by one or two phenyl groups, a C_{2-10} alkenyl group, a C_{2-10} alkynyl group, a hydroxyl C_{2-10} alkyl group, a C_{1-10} alkyl group, a C_{1-10} alkyl group, an amino C_{2-10} alkyl group or a C_{1-10} alkyl group; X represents a hydrogen atom or a fluorine atom;

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92272

Application No.: 10/562,010

Y represents an amino group, -SR³, -S(O)_nR⁷, -SCHR³R⁴, -S(O)_nCHR³R⁴, -NHCHR³R⁴, -NHCHR³R

 R^7 represents a C_{1-10} alkyl group, a phenyl group, a naphthyl group, a naphthyl group substituted by one to seven halogen atoms or a hetroaromatic group or represents "a phenyl group substituted by one to five substituents selected from a group consisting of a halogen, a phenyl group, a C_{1-10} alkyl group, a C_{1-10} alkoxy group and a trifluoromethyl group"; and n represents integer 1 or 2)].

- 3. (Original) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [II] wherein R² represents a hydrogen.
- 4. (Original) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [II] wherein R¹ and R² each represents a hydrogen.

5-6. (Canceled)

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/562,010

Attorney Docket No.: Q92272

7. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [II] wherein R¹ and R² each represents a hydrogen atom;

X represents a fluorine atom; and

Y represents $-SR^3$ (- SR^3 is the same as mentioned above).

8. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, represented by formula [II] wherein R¹ and R² each represents a hydrogen atom;

X represents a fluorine atom; and

Y represents $-S(O)_nR^7$ ($-S(O)_nR^7$ is the same as mentioned above).

9-21. (Canceled)

22. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, such a compound of formula [II] being:

(1R,2S,3R,5R,6R)-2-amino-3-(thiophene-2-ylmethylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(2-phenylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(4-methoxybenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

Application No.: 10/562,010

(1R,2S,3R,5R,6R)-2-amino-3-(4-fluorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(4-t-butylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3-trifluoromethylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R, 2S, 3R, 5R, 6R) - 2-amino - 3 - (1-bromo-naphthalene - 2-ylmethylsulfanyl) - 6-amino - 3 - (1-bromo-naphthalene - 3 - (1-bromo-naphtha

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R) 2-amino-3-(3,4-dichlorobenzylsulfanyl) bicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorophenylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(3-chloro-2,6-difluorobenzylsulfanyl)-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-(propylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92272

Application No.: 10/562,010

(1R,2S,3R,5R,6R)-2-amino-3-(1-phenyl-ethylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2S,3R,5R,6R)-2-amino-3-[bis-(4-fluorophenyl)methylsulfanyl]-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2R,3R,5R,6R)-2,3-diamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2R,3R,5R,6R)-2-amino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid;

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid; or

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.

23. (Currently Amended) A 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, a pharmaceutically acceptable salt thereof or a hydrate thereof, such a compound of formula [II] being:

(1R,2R,3R,5R,6R)-2,3-diamino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(thiophene-2-ylmethylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(2-phenylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

Application No.: 10/562,010

(1R,2S,3R,5R,6R)-2-amino-3-(4-methoxybenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(4-fluorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(4-t-butylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3-trifluoromethylbenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(1-bromo-naphthalene-2-ylmethylsulfanyl)-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R) 2-amino-3-(3,4-dichlorobenzylsulfanyl)-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfinyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfonyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorophenylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3-chloro-2,6-difluorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/562,010

Attorney Docket No.: Q92272

(1R,2S,3R,5R,6R)-2-amino-3-(propylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(1-phenyl-ethylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-[bis-(4-fluorophenyl)methylsulfanyl]-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2R,3R,5R,6R)-2-amino-3-[N,N-(3,4-dichlorobenzyl)methylamino]-6-

fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoylamino)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester;

(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzoyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 2-ethyl ester;

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-isobutyl ester; or

(1R,2S,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzylsulfanyl)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-benzyl ester.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q92272

Application No.: 10/562,010

24. (Previously Presented) A drug comprising the 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 1, the pharmaceutically acceptable salt thereof or the hydrate thereof as an active ingredient.

25. (Original)The drug according to claim 24 wherein the drug is a Group II metabotropic glutamate receptor antagonist.